Newport Laboratories, Inc., a leader in custom-made vaccines, today launches Bio One™, a new, proprietary one-dose adjuvant that helps reduce time, labor and expense by removing the need for booster shots.
Many bovine custom-made vaccines require an initial administration and a second booster shot several weeks later, but due to the added labor cost and logistical challenges associated with administering the second dose, it is commonly overlooked. This can compromise the effectiveness of the vaccine.
BIO ONE, which is available exclusively from Newport Laboratories, delays the elimination of antigens, and thus permits immune responses to last longer,1 removing the need for a second dose.
“Making it easier for producers and veterinarians to keep their herds healthy is at the core of what we do at Newport Laboratories,” said Randy Shirbroun, DVM, director of the Ruminant Business Unit at Newport Laboratories. “We’ve heard from our customers that administering a second dose of a vaccine is time consuming and costly, so we’re excited that BIO ONE will remove that extra step.”
There are two basic ingredients in killed vaccines: antigens and adjuvants. Antigens are viruses or bacteria that have been inactivated so they don’t cause disease. But even in an inactivated state, antigens do set off an alarm within the immune system, signaling that a foreign invader is present. It’s the job of the adjuvant to amplify that alarm, which allows the immune system to begin building up its defenses against the invader, making it better prepared to fend off the real thing.
Unlike off-the-shelf killed vaccines, custom-made vaccines give producers and veterinarians the option to select an adjuvant that can help solve their particular herd’s health challenges. Determining the optimal adjuvant to use in a vaccine is critical, because different adjuvants have different abilities when triggering immune responses.2
To learn more about how you can reduce stress in your herd and start saving time with BIO ONE, contact your Newport Laboratories or Boehringer Ingelheim representative, or click here.
References
1 National Institute of Allergy and Infectious Diseases (NIH). Vaccine adjuvants. 2019. Available at: http://www.niaid.nih.gov/research/vaccine-adjuvants. Accessed April 12, 2019.
2 Krishnan L, Dicaire CJ, Patel GB, Sprott GS. Archaeosome vaccine adjuvants induce strong humoral, cell-mediated and memory responses: comparison to conventional liposomes and alum. Infection and Immunity 2000;68(1):54–63. Available at: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC97101/pdf/ii000054.pdf. Accessed April 12, 2019.
About Newport Laboratories
Newport Laboratories, Inc. is a Boehringer Ingelheim company and the nation’s leading manufacturer of custom-made vaccines. Located in Worthington, Minnesota, Newport Laboratories assists veterinarians and livestock producers in their efforts to address animal health problems through cutting-edge diagnostic testing and production of high-quality, evidence-based, custom-made vaccines. For further information, call 800-220-2522, email info@newportlabs.com, or visit the Newport Laboratories website at http://www.newportlabs.com.
About Boehringer Ingelheim Animal Health USA Inc.
Boehringer Ingelheim is the second largest animal health business in the world, with net sales of almost $4.7 billion (3.9 billion euros) worldwide in 2018, about 10,000 employees and a presence in more than 150 markets. We have pioneered advancements in vaccines, parasite-control products and therapeutics that limit pain and slow disease, and we aim to create the future of animal wellbeing for pets, horses and livestock by focusing on prevention.
Boehringer Ingelheim’s Animal Health Business has a significant presence in the United States, with more than 3,000 employees in places that include Georgia, Missouri, Iowa, Minnesota, New Jersey and Puerto Rico. To learn more, visit www.boehringer-ingelheim.us, www.facebook.com/BoehringerAHUS or www.twitter.com/Boehringer_AH.
About Boehringer Ingelheim
Improving the health of humans and animals is the goal of the research-driven pharmaceutical company Boehringer Ingelheim. The focus in doing so is on diseases for which no satisfactory treatment option exists to date. The company therefore concentrates on developing innovative therapies that can extend patients’ lives. In animal health, Boehringer Ingelheim stands for advanced prevention.
Family-owned since it was established in 1885, Boehringer Ingelheim is one of the pharmaceutical industry’s top 20 companies. Some 50,000 employees create value through innovation daily for the three business areas: human pharmaceuticals, animal health and biopharmaceuticals. In 2018, Boehringer Ingelheim achieved net sales of around $20.7 billion (17.5 billion euros). R&D expenditure of about $3.8 billion (3.2 billion euros), corresponded to 18.1 per cent of net sales.
As a family-owned company, Boehringer Ingelheim plans in generations and focuses on long-term success. The company therefore aims at organic growth from its own resources with simultaneous openness to partnerships and strategic alliances in research. In everything it does, Boehringer Ingelheim naturally adopts responsibility towards mankind and the environment.
